$C4 Therapeutics (CCCC.US)$ C4 Therapeutics Presents Cemsido...

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Positive
36% overall response rate and 45% clinical benefit rate achieved in MM at highest dose level
38% overall response rate in NHL across all subtypes
44% overall response rate in PTCL specifically
No treatment emergent adverse events leading to dose reduction
Well-tolerated safety profile across both MM and NHL trials

Negative
Two dose-limiting toxicities occurred at the 100 µg QD dose level in NHL trial
Common Grade 3 or above adverse events included neutropenia, anemia, and infections